- Conditions
- HIV Infection
- Interventions
- Rifampicin 600 mg
- Drug
- Lead sponsor
- Drexel University
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2785–2808
of 16,863
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Skin Ulcers, Sickle Cell Anemia
- Interventions
- Arginine Butyrate, Standard local care dressing
- Drug · Other
- Lead sponsor
- Susan P. Perrine
- Other
- Eligibility
- 16 Years to 60 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2005
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Dry Eye Syndromes
- Interventions
- Self retained cryopreserved amniotic membrane, lifitegrast ophthalmic solution
- Device · Other
- Lead sponsor
- BioTissue Holdings, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- HIV Infections
- Interventions
- Buprenorphine, Tipranavir and ritonavir
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- HIV Infections
- Interventions
- Atazanavir, Nelfinavir mesylate
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 47
- States / cities
- Little Rock, Arkansas • Berkeley, California • Fountain Valley, California + 37 more
- Conditions
- Cushing's Disease
- Interventions
- mifepristone
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 6 Years to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- RDS of Prematurity, Preterm Birth, Lung Diseases
- Interventions
- Lung monitoring with the Neola device
- Device
- Lead sponsor
- Neola Medical Inc
- Industry
- Eligibility
- 1 Day to 44 Weeks
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Camden, New Jersey
- Conditions
- HIV Infections, Cardiovascular Disease
- Interventions
- rosuvastatin
- Drug
- Lead sponsor
- University of Hawaii
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Pain, Intractable
- Interventions
- Spinal Cord Stimulation (SCS)
- Device
- Lead sponsor
- MedtronicNeuro
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • Chula Vista, California • Wilmington, Delaware + 8 more
- Conditions
- Sudden Infant Death Syndrome
- Interventions
- Lifestyle Counseling
- Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 616 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2015
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Sleep Apnea, Heart Failure
- Interventions
- Adaptive Servo Ventilation
- Device
- Lead sponsor
- Toronto Rehabilitation Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 732 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Kalispell, Montana • Cleveland, Ohio
- Conditions
- Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
- Interventions
- MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
- Drug
- Lead sponsor
- AVEM HealthCare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Panorama City, California
- Conditions
- Pelvic Pain Syndrome, Groin Pain, Meralgia Paresthetica, Low Back Pain, Perineal Neuralgia
- Interventions
- MR neurography-guided cryoanalgesia
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Mucopolysaccharidosis II
- Interventions
- tividenofusp alfa
- Drug
- Lead sponsor
- Denali Therapeutics Inc.
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Oakland, California • Chicago, Illinois • Hackensack, New Jersey + 5 more
- Conditions
- Gulf War Syndrome, Adult Growth Hormone Deficiency
- Interventions
- Recombinant human growth hormone
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Houston, Texas • Seattle, Washington
- Conditions
- Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Clinically Isolated Syndrome
- Interventions
- Not listed
- Lead sponsor
- John F. Foley, MD
- Other
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
- Interventions
- Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more
- Conditions
- Chronic Rhinosinusitis
- Interventions
- Checklist introduction / Pause
- Behavioral
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea
- Interventions
- Rifaximin, Glucose and lactulose hydrogen breath testing
- Drug · Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Substance Abuse, HIV Infections
- Interventions
- Bupropion, Placebo
- Drug
- Lead sponsor
- San Francisco Department of Public Health
- Government
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Alport Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 5 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- HIV Infection, Diabetes Mellitus Type 2, Obesity, Overweight, Metabolic Syndrome
- Interventions
- Liraglutide
- Drug
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HIV Infections, Hepatitis C
- Interventions
- Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 24
- States / cities
- San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
- Conditions
- CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL), Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
- Interventions
- Lonitoclax (ZE50-0134)
- Drug
- Lead sponsor
- Lomond Therapeutics Holdings, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Louisville, Kentucky • Chapel Hill, North Carolina • Cincinnati, Ohio + 2 more